171 related articles for article (PubMed ID: 32598478)
1. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.
Macek TA; Suzuki K; Asin K; Kimura H
Int J Neuropsychopharmacol; 2020 Nov; 23(8):524-532. PubMed ID: 32598478
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events.
Goldsmith P; Affinito J; McCue M; Tsai M; Roepcke S; Xie J; Gertsik L; Macek TA
Drugs R D; 2017 Dec; 17(4):631-643. PubMed ID: 29103081
[TBL] [Abstract][Full Text] [Related]
3. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
Suzuki K; Harada A; Shiraishi E; Kimura H
J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
[TBL] [Abstract][Full Text] [Related]
5. A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor.
Takano A; Stenkrona P; Stepanov V; Amini N; Martinsson S; Tsai M; Goldsmith P; Xie J; Wu J; Uz T; Halldin C; Macek TA
Neuroimage; 2016 Nov; 141():10-17. PubMed ID: 27423256
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.
Yurgelun-Todd DA; Renshaw PF; Goldsmith P; Uz T; Macek TA
Psychopharmacology (Berl); 2020 Feb; 237(2):317-328. PubMed ID: 31773211
[TBL] [Abstract][Full Text] [Related]
7. Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [11 C]T-773 in nonhuman primates.
Takano A; Stepanov V; Nakao R; Amini N; Gulyás B; Kimura H; Halldin C
Synapse; 2016 Jun; 70(6):253-63. PubMed ID: 26878349
[TBL] [Abstract][Full Text] [Related]
8. TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge.
Tomimatsu Y; Cash D; Suzuki M; Suzuki K; Bernanos M; Simmons C; Williams SC; Kimura H
Neuroscience; 2016 Dec; 339():180-190. PubMed ID: 27725212
[TBL] [Abstract][Full Text] [Related]
9. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
10. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
[TBL] [Abstract][Full Text] [Related]
11. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor.
Harada A; Suzuki K; Kamiguchi N; Miyamoto M; Tohyama K; Nakashima K; Taniguchi T; Kimura H
PLoS One; 2015; 10(3):e0122197. PubMed ID: 25815469
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.
Tsai M; Chrones L; Xie J; Gevorkyan H; Macek TA
Psychopharmacology (Berl); 2016 Oct; 233(21-22):3787-3795. PubMed ID: 27572830
[TBL] [Abstract][Full Text] [Related]
13. TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.
Suzuki K; Kimura H
CNS Neurosci Ther; 2018 Jul; 24(7):604-614. PubMed ID: 29318783
[TBL] [Abstract][Full Text] [Related]
14. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia.
Macek TA; McCue M; Dong X; Hanson E; Goldsmith P; Affinito J; Mahableshwarkar AR
Schizophr Res; 2019 Feb; 204():289-294. PubMed ID: 30190165
[TBL] [Abstract][Full Text] [Related]
15. Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.
Masilamoni GJ; Uthayathas S; Koenig G; Leventhal L; Papa SM
Neuropharmacology; 2016 Nov; 110(Pt A):449-457. PubMed ID: 27539962
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.
Suzuki K; Harada A; Suzuki H; Capuani C; Ugolini A; Corsi M; Kimura H
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417763
[TBL] [Abstract][Full Text] [Related]
17. The phosphodiesterase 10A selective inhibitor, TAK-063, induces c-Fos expression in both direct and indirect pathway medium spiny neurons and sub-regions of the medial prefrontal cortex in rats.
Nakatani A; Nakamura S; Kimura H
Neurosci Res; 2017 Dec; 125():29-36. PubMed ID: 28687229
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 10A Is a Critical Target for Neuroprotection in a Mouse Model of Ischemic Stroke.
Beker MC; Caglayan AB; Altunay S; Ozbay E; Ates N; Kelestemur T; Caglayan B; Kilic U; Doeppner TR; Hermann DM; Kilic E
Mol Neurobiol; 2022 Jan; 59(1):574-589. PubMed ID: 34735672
[TBL] [Abstract][Full Text] [Related]
19. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
Harada A; Suzuki K; Kimura H
J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
Harada A; Suzuki K; Miura S; Hasui T; Kamiguchi N; Ishii T; Taniguchi T; Kuroita T; Takano A; Stepanov V; Halldin C; Kimura H
Nucl Med Biol; 2015 Feb; 42(2):146-54. PubMed ID: 25451212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
